Q-omics provides the consensus-scored GLYCTK profile across patient tissues and cancer cell-line models. GLYCTK expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GLYCTK is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, GLYCTK RNA expression shows 18,216 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UVM, KIRP, and TGCT as cancer lineages where GLYCTK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GLYCTK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GLYCTK survival associations across molecular data types. GLYCTK RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GLYCTK RNA expression–survival associations across cancer types. High GLYCTK expression shows unfavorable associations in UVM and ACC, but favorable associations in HNSC, KIRP, BLCA and THYM. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for GLYCTK RNA expression.
This table summarizes GLYCTK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GLYCTK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GLYCTK shows lower tumor expression in KIRP, KICH, BRCA, LUSC, LUAD and CHOL. The KIRP box plot shows higher GLYCTK RNA expression in normal versus tumor tissue (log2 FC = −1.310, t-test p < 0.001).
This table shows molecular features associated with GLYCTK in patient tissues and cancer cell lines. In patient samples, GLYCTK shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GLYCTK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Lymphoma.
